Suppr超能文献

基于体重的肝素剂量图谱与传统肝素给药以实现治疗性抗凝的比较。

Comparison of a weight-based heparin nomogram with traditional heparin dosing to achieve therapeutic anticoagulation.

作者信息

Shalansky K F, FitzGerald J M, Sunderji R, Traboulay S J, O'Malley B, McCarron B I, Naiman S

机构信息

Department of Pharmacy, Vancouver Hospital and Health Sciences Centre, British Columbia, Canada.

出版信息

Pharmacotherapy. 1996 Nov-Dec;16(6):1076-84.

PMID:8947981
Abstract

Optimum anticoagulation with heparin within the first 24 hours of a thrombotic event is critical in preventing a recurrence. We believed that traditional nonweight-based heparin dosing at our institution resulted in delayed anticoagulation. A weight-based heparin nomogram was therefore created and compared to traditional heparin dosing in patients with a diagnosis of acute deep vein thrombosis or pulmonary embolism. Fifty historical control patients were compared to 50 consecutive patients treated prospectively using the weight-based nomogram. The primary outcome assessed was time to achieve therapeutic anticoagulation, defined as an activated partial thromboplastin time (aPTT) of 46-70 seconds (1.5-2.5 times the control aPTT). The weight-based nomogram achieved an aPTT above the therapeutic threshold more rapidly than the control group (10.7 hrs nomogram vs 33.3 hrs control group, p < 0.004). Similarly, the proportion of patients who exceeded the therapeutic threshold at the first aPTT measurement, at 24 hours, and at 48 hours was significantly higher in the nomogram group. There was no difference in the frequency of bleeding complications or recurrent thrombotic events between the two groups. The initial nomogram was revised for patients weighing more than 80 kg owing to a greater frequency of excessive anticoagulation in these patients. Subsequent analysis of 29 patients using the modified nomogram revealed sustained efficacy and a reduced number of supratherapeutic aPTTs. We concluded that a weight-based heparin nomogram is superior to traditional therapy in achieving rapid therapeutic anticoagulation without an increase in adverse outcomes.

摘要

在血栓形成事件的头24小时内,使用肝素进行最佳抗凝对于预防复发至关重要。我们认为,我们机构传统的非体重基础肝素给药导致抗凝延迟。因此,我们制定了基于体重的肝素剂量表,并将其与诊断为急性深静脉血栓形成或肺栓塞患者的传统肝素给药进行比较。将50例历史对照患者与50例前瞻性使用基于体重剂量表治疗的连续患者进行比较。评估的主要结局是达到治疗性抗凝的时间,定义为活化部分凝血活酶时间(aPTT)为46 - 70秒(对照aPTT的1.5 - 2.5倍)。基于体重的剂量表比对照组更快地使aPTT超过治疗阈值(剂量表组为10.7小时,对照组为33.3小时,p < 0.004)。同样,在剂量表组中,首次aPTT测量时、24小时时和48小时时超过治疗阈值的患者比例显著更高。两组之间出血并发症或复发性血栓形成事件的发生率没有差异。由于体重超过80 kg的患者过度抗凝的频率更高,因此对初始剂量表进行了修订。随后对29例使用修订后剂量表的患者进行分析,结果显示疗效持续且超治疗性aPTT的数量减少。我们得出结论,基于体重的肝素剂量表在实现快速治疗性抗凝方面优于传统疗法,且不会增加不良结局发生的风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验